World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 21 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: CTRI
Last refreshed on: 14 January 2019
Main ID:  CTRI/2017/07/009119
Date of registration: 27-07-2017
Prospective Registration: Yes
Primary sponsor: University College London
Public title: Clinical trial of treatment shortening for minimal tuberculosis in children.
Scientific title: A randomized trial of therapy shortening for minimal tuberculosis with new WHO-recommended doses / fixed-dose-combination drugs in African / Indian HIV+ and HIV- children : SHINE study. - SHINE STUDY
Date of first enrolment: 01-08-2017
Target sample size: 1200
Recruitment status: Open to Recruitment
URL:  http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=19671
Study type:  Interventional
Study design:  Randomized, Parallel Group Trial
Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Open Label
 
Phase:  Phase 3
Countries of recruitment
India South Africa Uganda Zambia
Contacts
Name: Dr Vidya Mave   
Address:  1st floor, Clinical Trials Unit, Pathology Museum, B J Medical College and Sassoon General hospitals, Jai Prakash Narayan road, Pune 600031 Pune, MAHARASHTRA India
Telephone:
Email: bhavani.pk@nirt.res.in
Affiliation:  National Institute for Research in Tuberculosis
Name: Dr P K Bhavani   
Address:  Room No. 207, Department of Clinical Research, National Institute for Research in Tuberculosis, No.1, Mayor Sathyamoorthy Road, Chetpet, Chennai 600031 Chennai, TAMIL NADU India
Telephone:
Email: bhavani.pk@nirt.res.in
Affiliation:  National Institute for Research in Tuberculosis
Key inclusion & exclusion criteria
Inclusion criteria: 1. Age 0-16 years



2. Weight â?¥ 3kg. This has been expanded to include children weighing between 3 and 4kg; a detailed PK study of individual drugs in infants is ongoing and data using the new FDC from this study will ensure that use of this new formulation is also studied in these smallest infants.



3. Clinician has decided to treat with standard first-line regimen (intensive phase of 4 drugs or 3 drugs as per local practice)



4. Symptomatic but non-severe TB including:

a. extrathoracic lymph node TB; intra-thoracic uncomplicated (hilar) lymph node TB

b. minimal or no parenchymal abnormality on CXR

c. smear gastric aspirate/other respiratory sample (minimum 2 samples) negative

Note: GeneXpert may be positive or negative; culture of respiratory sample may be positive or negative; lymph node aspirate may be smear/culture/GeneXpert positive or negative)



5. Not previously treated for TB or successfully treated for TB > 2 years since last completed treatment



6. Known HIV status; HIV-infected or HIV-uninfected



7. Willing and likely to adhere to 72 weeks follow up



8. Informed written consent from the parent/legal caregiver(s) and assent in children, as per local Ethics Committee guidance



9. Home address accessible for visiting and intending to remain within the recruitment area for follow up



10. Since participants will all be under legal age of independent consent, a parent or legal guardian must be willing and able to provide informed consent. If the subject is of appropriate age, she/he will also be asked to give assent if developmentally appropriate and clinically possible.

11. Participant can comply with the protocol requirements in the opinion of the site investigator.


Exclusion criteria: 1. Smear-positive respiratory sample TB (note: smear-positive peripheral lymph node sample is allowed)



2. Premature ( <37 weeks) and aged under 3 months



3. Miliary TB, spinal TB, TB meningitis, osteo articular TB, abdominal TB, congenital TB



4. Pre-existing non-tuberculous disease likely to prejudice the response to, or assessment of, treatment e.g. liver or kidney disease, peripheral neuropathy, cavitation



5. Any known contraindication to taking anti-TB drugs



6. Known contact with drug resistant adult source case (including mono-resistant TB)



7. Known drug resistance in the child



8. Severely sick



9. Pregnancy



10. A clinically significant active medical condition or the presence of any concomitant severe illness or rapidly deteriorating health condition (outside of TB), which, in the opinion of the site investigator, would prevent appropriate participation in the trial, or that would make implementation of the protocol or interpretation of the study results difficult, or otherwise make the subject a poor candidate for a clinical trial.



Age minimum:
Age maximum:
Gender:
Health Condition(s) or Problem(s) studied
Minimal Tuberculosis in Children.
Intervention(s)
Intervention1: ATT given for 4 months duration: Intensive phase 2 months of HRZE (Isoniazid H,Rifampicin R, Pyrazinamide Z, Ethambutol E) daily &
Continuation phase 2 months of HRE (Isoniazid H, Rifampicin R, Ethambutol E) daily.
Control Intervention1: ATT given for 6 months duration: Intensive phase 2 months of HRZE (Isoniazid H,Rifampicin R, Pyrazinamide Z, Ethambutol E) daily &
Continuation phase 4 months of HRE (Isoniazid H, Rifampicin R, Ethambutol E) daily.
Primary Outcome(s)
TB disease free survival 72 weeks post randomisation will be determined by the ERC and categorised as:

1. Favourable

2.Unfavourable (including death, reinfection or relapse) or

3. Not assessable (e.g. lost to follow-up)

------Timepoint: 72 weeks post randomisation
Secondary Outcome(s)
1. Mortality

2. Adverse drug reactions within 30 days of completing treatment

3. Relapse/re-infection-free survival including only cases adjudicated to be TB by the independent ERC

4. Suppressed HIV viral load at 24 and 48 weeks in HIV-infected children

5. Adherence and acceptability

6. Bacterial infections (requiring hospitalisation)



------Timepoint: 72 weeks post randomisation
Secondary ID(s)
ISRCTN 63579542
Version 2.1, dated 14 DEC 2015
Source(s) of Monetary Support
University College London, MRC Clinical Trials Unit, Aviation House, 125 Kingsway, London,WC2B 6NH. UK
Secondary Sponsor(s)
B J Medical College and Sassoon General hospitals Pune
Government Stanley Medical College Hospital Institute of Social Pediatrics Chennai
Madras Medical College Institute of Child Health and Hospital for Children Chennai
National Institute for Research in Tuberculosis Chennai
Ethics review
Results
Results available:
Date Posted:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history